| Lorene S Valdez-boyle, MD | |
|
801 Encino Pl, Ne Suite C1, Unmhsc Specialty Extension Services, Albuquerque, NM 87102 | |
| (505) 272-0110 | |
| (505) 272-2360 |
| Full Name | Lorene S Valdez-boyle |
|---|---|
| Gender | Female |
| Speciality | Colon & Rectal Surgery |
| Location | 801 Encino Pl, Ne Suite C1, Albuquerque, New Mexico |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1780650986 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208600000X | Surgery | 20050754 (New Mexico) | Secondary |
| 208C00000X | Colon & Rectal Surgery | 20050754 (New Mexico) | Primary |
| Entity Name | Presbyterian Healthcare Services |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1104802354 PECOS PAC ID: 9234041708 Enrollment ID: O20031103000603 |
News Archive
Primary care physicians are failing to meet guidelines for hepatitis A virus and hepatitis B virus vaccination in patients with chronic hepatitis C infection, according to US research.
A generic drug already used by millions of Americans for high blood pressure and prostate problems has been found to improve sleep and lessen trauma nightmares in veterans with posttraumatic stress disorder (PTSD).
A biochemistry research team led by Dr. Andrew H.-J. Wang and Dr. Ting-Fang Wang at the Institute of Biological Chemistry, Academia Sinica(IBCAS), has discovered that the RecA family recombinases function as a new type of rotary motor proteins to repair DNA damages.
Curis, Inc., a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that positive data are being presented by its collaborator Genentech, a member of the Roche Group, from a pivotal Phase II clinical trial conducted by Roche and Genentech of vismodegib in patients with advanced basal cell carcinoma, an often life-threatening form of skin cancer that can have disfiguring and debilitating effects.
Ingen Technologies, Inc. (Pink Sheets:IGNT), an emerging medical device manufacturer developing innovative solutions for the respiratory market, with a new patented and proprietary medical product line targeting the $8B respiratory market, announced today that the company has also filed a U.S patent and will begin the required manufacturing processes to produce the new drug insulin thermos product.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Lorene S Valdez-boyle, MD 801 Encino Pl, Ne Suite C1, Unmhsc Specialty Extension Services, Albuquerque, NM 87102 Ph: (505) 272-0110 | Lorene S Valdez-boyle, MD 801 Encino Pl, Ne Suite C1, Unmhsc Specialty Extension Services, Albuquerque, NM 87102 Ph: (505) 272-0110 |
News Archive
Primary care physicians are failing to meet guidelines for hepatitis A virus and hepatitis B virus vaccination in patients with chronic hepatitis C infection, according to US research.
A generic drug already used by millions of Americans for high blood pressure and prostate problems has been found to improve sleep and lessen trauma nightmares in veterans with posttraumatic stress disorder (PTSD).
A biochemistry research team led by Dr. Andrew H.-J. Wang and Dr. Ting-Fang Wang at the Institute of Biological Chemistry, Academia Sinica(IBCAS), has discovered that the RecA family recombinases function as a new type of rotary motor proteins to repair DNA damages.
Curis, Inc., a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that positive data are being presented by its collaborator Genentech, a member of the Roche Group, from a pivotal Phase II clinical trial conducted by Roche and Genentech of vismodegib in patients with advanced basal cell carcinoma, an often life-threatening form of skin cancer that can have disfiguring and debilitating effects.
Ingen Technologies, Inc. (Pink Sheets:IGNT), an emerging medical device manufacturer developing innovative solutions for the respiratory market, with a new patented and proprietary medical product line targeting the $8B respiratory market, announced today that the company has also filed a U.S patent and will begin the required manufacturing processes to produce the new drug insulin thermos product.
› Verified 8 days ago